Two Year Real World Data

Great Results. Period.

Real-world evidence from two years of iLet commercial availability demonstrates:

Shown to significantly lower A1c¹

Users experienced a significant and sustainable reduction from starting A1c to GMI while using the iLet.

Shown to dramatically increase in TIR¹

Users experienced a significant and sustainable increase in Time in Range from baseline therapy.

Less Effort. Great Results²

The iLet Bionic Pancreas System required much less effort from patients, with improved results consistent across high and low levels of patient engagement.

Reduced Burden for Providers

The iLet Bionic Pancreas System positively impacted all patient types, while reducing burden and time spent managing patients.

Low Time in Hypo¹

The reduction in average glucose and increased time in range were achieved while maintaining a median time 54 mg/dL of 0.3% – about 1/4th the ADA goal of ≤1%..

Real-World Evidence

Two years of real-world evidence showed that adults and children who switched to the iLet achieved a 1.6% improvement in HbA1c to GMI.³

The iLet is designed to require minimal patient engagement and the fewest healthcare provider–adjustable parameters. By autonomously making 100% of dosing decisions, it alleviates the patient burden of carb counting* and manual dose calculations while achieving optimal glycemic outcomes.

^*User must be carb aware.

Low Time in Hypo

The iLet achieved median time 54 mg/dL of 0.3% – about 1/4th the ADA goal.³

The iLet demonstrated very low rates of hypoglycemia (well below ADA-recommended targets), and published data indicate that patients experience the same or fewer episodes of hypoglycemia compared with other AID systems currently available.

1 Russell, S.J., et al. (2022) A Multicenter Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. The New England Journal of Medicine 2022; 387:1161–1172. RCT comparing 3 months of iLet use to standard of care in 440 people aged 6-83 years with type 1 diabetes. 2 Weissberg-Benchell, J., et.al (2023). Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes. DTT, 10.1089/dia.2023.0238. 3 Data on file. The postmarket surveillance data presented are observational data. These data do not come from a prospective study designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by baseline HbA1c. Data comes from a real-world population from the first 2 years (5/19/2023-5/28/2025) of iLet usage among those people who had baseline HbA1c data available and who uploaded at least two weeks’ worth of CGM data to Beta Bionics, Inc., including users who do not meet all criteria in the Indications for Use. Individual user results may vary from the average values shown here.

MM000205_B

Ready to GO BIONIC?

The iLet Bionic Pancreas automatically adjusts to your insulin needs so you don’t have to.

GO BIONIC

Two Year Real World Data

Great Results. Period.

Real-world evidence from two years of iLet commercial availability demonstrates:

Shown to significantly lower A1c1

Shown to dramatically increase in TIR1

Less Effort. Great Results2